Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products.
$111.60-2.29%
报价 2026-11-13
市值
$7.35B
EV
$8.05B
PE (TTM)
–
预期 PE (FY2027)
–
52 周区间距高点 -45.6%
$25.45$205.00
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中≈ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22028-09 | 1.5x | -2.09 → -0.87 | — |
| FY+32029-09 | 1.8x | -2.09 → -0.06 | — |
毛利率 52% · TTM 收入 $432M · 基数 EPS -2.09（调整后）
研究结论
L2 2026-05-22全文 ↓尚未生成 L3 估值，没有三情景目标价。去生成估值 →
L2 报告格式无法提取要点，请看全文。
历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TWSTTwist Bioscience Corporation | $7.35B | -2.3% | +20.2% | 53.1% | – | – | – | |
| EWTXEdgewise Therapeutics, Inc. | $4.94B | +0.2% | – | 0% | 4.9x | 4.1x | – | |
| VRDNViridian Therapeutics, Inc. | $3.51B | +1.3% | -12.1% | 93% | – | – | – | |
| GRDNGuardian Pharmacy Services, Inc. | $3.14B | +0.3% | +0.8% | 23% | 42.4x | 23.8x | 32.9x | |
| CLOVClover Health Investments, Corp. | $2.63B | +1.6% | +56.9% | 17.1% | 292.4x | 162.9x | 20.0x | |
| MESOMesoblast Limited | $1.72B | +1.3% | – | 78.3% | – | – | – | |
| QUREuniQure N.V. | $1.67B | -3.3% | – | 22.8% | – | – | – | |
| PRCTPROCEPT BioRobotics Corporation | $1.37B | +1.2% | +21.1% | 66.3% | – | – | – | |
| GPCRStructure Therapeutics Inc. | $1.15B | +0.8% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +11.0% | 22.9% | 42.4x | 23.8x | 26.4x |
研究全文
财务报表
| Metric | 2026-09-30 Q4 2026 | 2026-06-30 Q3 2026 | 2026-03-31 Q2 2026 | 2025-12-31 Q1 2026 | 2025-09-30 Q4 2025 | 2025-06-30 Q3 2025 | 2025-03-31 Q2 2025 | 2024-12-31 Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $126.6M | $118.4M | $110.7M | $103.7M | $99M | $96.1M | $92.8M | $88.7M |
| Gross Margin | 53.1% | 52.8% | 51.6% | 52% | 51.3% | 53.4% | 49.6% | 48.3% |
| Operating Margin | -25% | -30.6% | -34.9% | -31.7% | -30.2% | -31.4% | -44.8% | -39.1% |
| Net Income | $-20.6M | $-35.1M | $-44M | $-30.5M | $-27.1M | $20.4M | $-39.3M | $-31.6M |
| Diluted EPS | -0.31 | -0.56 | -0.71 | -0.5 | -0.45 | 0.33 | -0.66 | -0.53 |
| Operating Cash Flow | – | $1.1M | $-17.6M | $-24.8M | $-11.8M | $-1.4M | $-13M | $-21.4M |
研究材料
Filing 摘要